Kaitlyn Bader, Assistant Managing Editor

Firas G. Hougeir, MD, and clinician attendees discussed how to use real-world patient scenarios to determine optimal timing for biologic initiation for patients with moderate to severe HS.

DELTA CARE 1 is the first phase 3 investigation of a pan-JAK inhibitor specifically for lichen sclerosus.

Discover insights from the Horizons in Advanced Practice meeting on type 2 inflammation and psoriasis management.

Phase 1 cohort 4 data show soquelitinib demonstrated sustained clinical activity through 8 weeks, including in patients with prior systemic therapy exposure.

A Winter Clinical Hawaii poster determined that roflumilast cream 0.05% is well tolerated and effective for diverse patient populations with atopic dermatitis

Psoriasis impacts physical and emotional health, with hidden burdens like trauma and IPV affecting quality of life and care access.

At the Dermatology Times Horizons in Advanced Practice meeting in Tampa, Florida, conference chair Lakshi Aldredge, MSN, ANP-BC, DCNP, focused a discussion on efficacy data for adalimumab, secukinumab, and bimekizumab.

Mabwell’s investigational 9MW3811 is the first IL-11–targeting therapy to enter clinical evaluation for pathological scarring.

Discover key insights from the 2025 Fall Clinical Dermatology Conference, featuring advancements in eczema, skin cancer testing, and pediatric psoriasis therapies.

John Barbieri, MD, MBA; Ted Rosen, MD; Peter Lio, MD; Shanna Miranti, MPAS, PA-C; and Larissa Schmidt, DPM, share what gifts they would give to the field of dermatology this holiday season.

As 2025 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in vitiligo this year.

Hilary Baldwin, MD; Douglas DiRuggiero, DMSc, MHS, PA-C; Diego Ruiz DaSilva, MD; Ken Korber, PA-C; Patrick Burnett, MD, PhD; and Lisa Weiss, PA-C, share what gifts they would give to the field of dermatology this holiday season.

Experts discuss innovative strategies for vitiligo treatment, emphasizing the role of topical JAK inhibitors and effective patient communication for optimal outcomes.

At a recent Case-Based Roundtable event, Harrison Nguyen, MD, MBA, MPH, reviewed 2 HS patient cases and discussed the role of biologics.

Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed the 3 latest non-steroidal topicals for atopic dermatitis at the Horizons in Advanced Practice meeting.

Omar Noor, MD, recently presented 3 cases of psoriasis in older patients at Horizons in Advanced Practice to discuss available treatment options and considerations for Medicare and in-office injections.

At a recent Case-Based Roundtable® event, Aaron Farberg, MD, moderated a discussion of challenging atopic dermatitis cases spanning adult, adolescent, and pediatric patients.

Early-phase development introduces a potential first-in-class oral approach targeting type 2 inflammation relevant to dermatologic diseases.

At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, discussed psoriasis in high-impact sites, overall psoriatic disease, and available therapies.

Topline results are expected in the first quarter of 2026.

John Barbieri, MD, MBA, discusses how deteriorating prior authorization processes are compromising access to essential dermatologic therapies.

Omar Noor, MD, discusses how pain and functional impairment define CHE and reviews why topical delgocitinib provides early symptomatic relief and improved adherence.

Lakshi Aldredge, MSN, ANP-BC, DCNP, discussed key symptoms of CHE, the function of the JAK-STAT pathway, and key data from the DELTA trials evaluating delgocitinib cream at the Horizons in Advanced Practice meeting.

John Barbieri, MD, MBA, outlines how missing reviewer identification, unclear step-therapy requirements, and limited engagement during appeals contribute to delays, inefficiencies, and potential clinical harm for patients.

The first treatment follows Zevaskyn’s FDA approval as the first autologous, gene-modified cellular sheet designed to address RDEB wounds.

At a Dermatology Times Case-Based Roundtable event, Joe Gorelick, MSN, FNP-C, reviewed real-world strategies for hidradenitis suppurativa, highlighting growing preference for bimekizumab based on its dual IL-17A/IL-17F inhibition.

Omar Noor, MD, outlines the complex phenotypes, variable presentations, and functional burdens of chronic hand eczema and explains why a broader JAK-targeted strategy may offer therapeutic advantages.

At the Horizons in Advanced Practice meeting, Omar Noor, MD, led NP and PA attendees through 3 complex cases of atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

Citius Oncology’s IL-2 receptor–directed fusion protein offers rapid responses and pruritus improvement for relapsed or refractory stage I–III CTCL.

Discover the latest advancements in dermatology from the 2025 Elevate-Derm Fall Conference held in Tampa, Florida.